B O O K - American College of Rheumatology

ACR Poster Session A
174
394. Methothrexate Directly Inhibits RANKL Expression and
Osteoclasts Formation in Very Early Arthritis. Shankar Revu,
Petra Neregård, Erik Afklint and Anca Irinel Catrina, Department
of Medicine, Rheumatology Unit, Karolinska University Hopsital
and Karolinska Institute, Stockholm, Sweden.
395. Non-Infectious Pulmonary Complications of Biologic Agents
for Rheumatic Diseases – A Systematic Literature Review.
Andreas Hadjinicolaou 2 , Shweta Bhagat 1 and Andrew Ostor 1 ,
1
Rheumatology Research Unit, Addenbrooke’s Hospital,
Cambridge, Cambridge, United Kingdom, 2 University of
Cambridge, United Kingdom.
396. Parenteral MTX as an Initial Treatment Strategy for Early
Rheumatoid Arthritis: Results from a Nationwide Cohort.
Vivian P. Bykerk 2 , David S. Rowe 3 , Janet E. Pope 5 , CATCH
Scientific Advisory Committee 1 , Ashley Bonner 1 and J. Carter
Thorne 4 , 1 Canada, 2 Mt Sinai Hospital, Toronto, ON, Canada,
3
Saba University School of Medicine, Stouffville, ON, Canada,
4
Southlake Regional Health Care, Newmarket, ON, Canada, 5 St
Joseph Health Care London, London, ON, Canada.
397. Polymorphisms in the Folate Metabolism Gene MTHFR
(C677T and A1298C) Are Not Associated with Methotrexate
Adherence: Findings from the Veteran’s Affairs Rheumatoid
Arthritis (VARA) Registry. Lisa A. Davis 2 , Grant W. Cannon 5 ,
Roger Wolff 6 , Leah Haverhals 3 , Ted R. Mikuls 7 , Andreas M.
Reimold 1 , Gail S. Kerr 8 , John S. Richards 8 , Dannette S. Johnson 4
and Liron Caplan 2 , 1 Dallas VAMC, Dallas, TX, 2 Denver VAMC,
Aurora, CO, 3 Denver VAMC, 4 Jackson VAMC, Jackson, MS, 5 Salt
Lake City VAMC, Salt Lake City, UT, 6 Salt Lake City VAMC, 7 Univ
of Nebraska Med Ctr, Omaha, NE, 8 Washington, D.C. VAMC,
Washington, DC.
398. Pooled Analysis of Observational Studies on Lymphoma
Incidence among Rheumatoid Arthritis (RA) Patients Initiating
Etanercept Therapy. Peter McCroskery 2 , Virgil C. Dias 2 , Scott
Stryker 3 , Bojena Bitman 3 , Sean Z. Zhao 2 and Debra J. Zack 1 ,
1
Amgen Inc, Thousand Oaks, CA, 2 Amgen Inc., Thousand Oaks,
CA, 3 Amgen Inc.
399. Post-Marketing Surveillance Program of Tocilizumab for
RA in Japan – Interim Analyses of 3,881 Patients. Takao
Koike 2 , Masayoshi Harigai 8 , Shigeko Inokuma 3 , Naoki
Ishiguro 6 , Junnosuke Ryu 7 , Tsutomu Takeuchi 5 , Syuji Takei 4 ,
Yoshiya Tanaka 10 , Hisashi Yamanaka 9 and Kyoko Ito 1 , 1 Chugai
Pharmaceutical Co.Ltd, 2 Hokkaido University, Japan, 3 Japanese
Red Cross Medical Center, 4 Kagoshima University, Kagoshima
City, Japan, 5 Keio University, Toyko, Japan, 6 Nagoya University,
7
Nihon University, 8 Tokyo Medical and Dental University, Tokyo,
Japan, 9 Tokyo Womens Med Univ, Shinjuku-ku, Tokyo, Japan, 10 U
Occupa & Environ Hlth, Kitakyushu, Japan.
400. Predictive Risk Factors of Severe Infections in RA Patients
Treated with Abatacept in Real Life: Results from the
Orencia and Rheumatoid Arthritis (ORA) Registry. Jacques-
Eric Gottenberg 11 , Philippe Ravaud 5 , Thomas Bardin 7 , Patrice
Cacoub 6 , Aain Cantagrel 12 , Bernard Combe 9 , Maxime Dougados 3 ,
René-Marc Flipo 8 , Bertrand Godeau 4 , Loic Guillevin 3 , Eric
Hachulla 8 , Xavier Le Loët 10 , Thierry Schaeverbeke 2 , Jean
Sibilia 11 , Gabriel Baron 5 and Xavier Mariette 1 , 1 Bicetre Hospital,
2
Bordeaux Hospital, 3 Cochin Hospital, 4 Henri Mondor Hospital,
5
Hotel Dieu Hospital, 6 La Pitié Hospital, 7 Lariboisière Hospital,
8
LIlle Hospital, 9 Montpellier Hospital, 10 Rouen Hospital,
11
Strasbourg Hospital, 12 Toulouse Hospital.
401. Pregnancy Outcomes in Patients with Autoimmune Diseases
Treated with Rituximab. Eliza F. Chakravarty 1 , Elaine Murray 2 ,
Ariella Kelman 2 and Pamela Farmer 3 , 1 Mountain View, CA,
2
Genentech, South San Francisco, CA, 3 Genentech.
2010 Program Book
402. Pulmonary Function in Patients with Rheumatoid Arthritis
Treated with Anti-TNF Biologic Agents. Andrew J. Odden 1 , Ann
J. Impens 2 , Elena Schiopu 2 , Kevin Flaherty 1 and Kristine Phillips 2 ,
1
University of Michigan, 2 University of Michigan, Ann Arbor, MI.
403. Rate of Serious Infections in RA Patients Who Subsequently
Receive Other Biologic Therapies after Discontinuing
Rituximab Treatment. Mark C. Genovese 8 , Ferdinand
Breedveld 4 , Paul Emery 2 , Stanley B. Cohen 6 , Ed C. Keystone 9 ,
Eric L. Matteson 5 , Laura Burke 7 , Akiko Chai 3 , William Reiss 3 ,
Marianne Sweetser 1 and Tim Shaw 7 , 1 Biogen Idec, 2 Chapel
Allerton Hospital, Leeds, United Kingdom, 3 Genentech, 4 Leiden
Univ, 5 Mayo Clinic, Rochester, MN, 6 Rheumatology Associates,
Dallas, TX, 7 Roche, 8 Stanford Univ, Sunnyvale, CA, 9 University of
Toronto, Toronto, ON, Canada.
404. Rates of Tuberculosis and Nontuberculous Mycobacterial
Disease among Rheumatoid Arthritis Patients Who Use
Anti-Tumor Necrosis Factor alpha Therapy; from the SAfety
of Biologic ThERapy (SABER) Study. K. L. Winthrop 2 , John
Baddley 4 , Lang Chen 4 , Liyan Liu 1 , Carlos G. Grijalva 8 , Nivedita M.
Patkar 3 , Fenlong Xie 4 , Elizabeth Delzell 4 , Timothy Beukelman 6 ,
Lisa J. Herrinton 1 , Kenneth G. Saag 7 and Jeffrey R. Curtis 5 ,
1
Kaiser-Permanente, 2 OSHU, 3 Univ of AL at Birmingham,
Birmingham, AL, 4 Univ of AL at Birmingham, 5 University
of Alabama-Brimingham, Birmingham, AL, 6 University of
Alabama-Birmingham, Birmingham, AL, 7 University of Alabama-
Birmingham, Birmingham, AL, 8 Vanderbilt.
405. Real Life Analysis of the Romanian Experience in Switching
from Anti-TNF Based Therapy to Rituximab. Ioan Ancuta 1 ,
Catalin Codreanu 2 , Ruxandra Maria Ionescu 4 , Horatiu Bolosiu 5 ,
Magda Parvu 3 and Lia Georgescu 6 , 1 ”Dr. I. Cantacuzino” Hospital,
Bucharest, Romania, 2 ”Dr. I. Stoia” Center for Rheumatic
Diseases, Bucharest, Romania, 3 ”N. Gh. Lupu” Clinical Hospital,
Bucharest, Romania, 4 ”Sfanta Maria” Clinical Hospital,
Bucharest, Romania, 5 Rheumatology Clinic, Cluj - Napoca,
Romania, 6 Rheumatology Clinic, Tirgu-Mures, Targu - Mures,
Romania.
406. Real Life Treatment with Rituximab in TNF Blocker Non-
Responders Is Superior to Treatment with a Second TNF
Blocker. Joern Kekow 4 , Ulf Müller-Ladner 2 , Hendrik Schulze-
Koops 1 , Ralf Link 3 , Steffen Breuer 3 and Monika Kobialko 3 ,
1
Division of Rheumatology, University of Munich, Germany,
2
Justus-Liebig University Giessen, Kerckhoff Clinic, Bad Nauheim,
Germany, 3 Roche Pharma AG, Grenzach-Wyhlen, Germany,
4
Specialized Hospital for Rheumatology & Orthopaedics,
Vogelsang-Gommern, Vogelsang-Gommern, Germany.
407. Risk of Malignancies in Patients with Rheumatoid Arthritis
Treated with Biologic Therapy: Meta-Analysis of Controlled
Trials. Maria A. Lopez-Olivo 4 , Juan A. Martinez-Lopez 2 , Jean H.
Tayar 7 , Jose Polo Cueto 5 , Eduardo N. Pollono 3 , M. Rosa Gonzales-
Crespo 1 , Stephanie Fulton 6 and Maria E. Suarez-Almazor 7 ,
1
Hospital 12 de Octubre, 2 Spanish Society of Rheumatology,
Spain, 3 Texas Tech University Health Science Center - Paul Foster
School of Medicine, 4 The University of Texas M.D. Anderson
Cancer Center, Houston, TX, 5 The University of Texas MD
Anderson Cancer Center, 6 University of Texas, MD Anderson
Cancer Center, Houston, TX, 7 UT M D Anderson Cancer Ctr,
Houston, TX.
408. Risk of Malignancy during Anti-TNF alfa Therapy in Patients
with Rheumatoid Arthritis: Systematic Review and Meta-
Analysis of Registries, Long-Term Extension Studies and
Randomized Controlled Trials. Pierre Le Blay 3 , Gael Mouterde 4 ,
Thomas Barnetche 1 and Bernard G. Combe 2 , 1 Bordeaux
University Hospital, 2 Hopital Lapeyronie, Montpellier, France,
3
Hopital Lapeyronie, France, 4 Hopital Lapeyronie.